# OnCo record all-leukemia (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/all-leukemia/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "all-leukemia" ;
  schema:name "Acute lymphoblastic leukaemia"@en ;
  schema:description "Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."@en ;
  schema:url <https://onco.cc/cancers/all-leukemia/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia> ;
  owl:sameAs <http://www.wikidata.org/entity/Q180664> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1410> ;
  onco:tag "heme" ;
  onco:related <https://onco.cc/roadmaps/paediatric-oncology-roadmap/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/bpdcn/>, <https://onco.cc/cancers/cll/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/technologies/cytogenetics-fish/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/menin/>, <https://onco.cc/targets/cd7/>, <https://onco.cc/targets/cd22/>, <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/kmt2a/> ;
  onco:drugs <https://onco.cc/drugs/clonoseq/>, <https://onco.cc/drugs/clofarabine/>, <https://onco.cc/drugs/nelarabine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/dexrazoxane/>, <https://onco.cc/drugs/rasburicase/>, <https://onco.cc/drugs/dorocubicel/>, <https://onco.cc/drugs/aminopterin/> ;
  onco:companies <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/autolus/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/adaptive-biotechnologies/>, <https://onco.cc/companies/ecog-acrin/>, <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:terms <https://onco.cc/terms/ph-positive-all/>, <https://onco.cc/terms/mrd-negative-cr/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/pci-term/> ;
  onco:trials <https://onco.cc/trials/ccss/>, <https://onco.cc/trials/nct07570173/>, <https://onco.cc/trials/aall0434/> ;
  onco:people <https://onco.cc/people/gertrude-elion/> ;
  onco:journals <https://onco.cc/journals/journal-of-pediatric-hematology-oncology/>, <https://onco.cc/journals/journal-of-pediatric-hematology-oncology-nursing/>, <https://onco.cc/journals/pediatric-hematology-and-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/mk-1045/>, <https://onco.cc/drugs/ucart22/>, <https://onco.cc/drugs/crc01/>, <https://onco.cc/drugs/tbi-1501/>, <https://onco.cc/drugs/obecabtagene-autoleucel/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/pairings/tki-plus-blinatumomab-ph-all/>, <https://onco.cc/ideas/idea-transplant-free-ph-all/>, <https://onco.cc/ideas/idea-menin-infant-all/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/pairings/blinatumomab-frontline-consolidation/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:standardOfCare <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/trials/aall1731/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/trials/aall1331/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/trials/interfant-06/>, <https://onco.cc/ideas/idea-menin-infant-all/>, <https://onco.cc/targets/kmt2a/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/trials/e1910/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/trials/graall-2005/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/trials/e1910/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/trials/phallcon/>, <https://onco.cc/trials/d-alba/>, <https://onco.cc/pairings/tki-plus-blinatumomab-ph-all/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/terms/mrd-negative-cr/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/obecabtagene-autoleucel/>, <https://onco.cc/trials/tower/>, <https://onco.cc/trials/ino-vate/>, <https://onco.cc/trials/felix/>, <https://onco.cc/trials/eliana/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/technologies/allogeneic-hsct/> .